# 1 Comparative adverse effects, perceptions and attitudes related to BNT162b2,

# 2 mRNA1273, or JNJ-78436735 SARS-CoV-2 vaccines: A population-based

- 3 longitudinal cohort
- 4
- 5 Authors
- 6 Oliver Bürzle<sup>1</sup>, Dominik Menges<sup>1</sup>, Julian D. Maier<sup>1</sup>, Daniel Schams<sup>1</sup>, Milo Puhan<sup>1</sup>, Jan Fehr<sup>1</sup>, Tala
- 7 Ballouz<sup>1\*</sup>, Anja Frei<sup>1\*</sup>
- 8
- 9 \* Shared last authorship due to equal contribution.
- <sup>1</sup> Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich (UZH), Zurich,
- 11 Switzerland
- 12
- 13 Corresponding Author
- 14 Anja Frei, PhD
- 15 Epidemiology, Biostatistics and Prevention Institute, University of Zurich
- 16 Hirschengraben 84, 8001 Zurich, Switzerland
- 17 E-Mail: anja.frei@uzh.ch | Phone: +41 44 634 43 60
- 18
- 19 Alternate Corresponding Author

It is made available under a CC-BY-NC-ND 4.0 International license .

- 20 Jan Fehr, MD
- 21 Epidemiology, Biostatistics and Prevention Institute, University of Zurich
- 22 Hirschengraben 84, 8001 Zurich, Switzerland
- 23 E-Mail: jan.fehr@uzh.ch | Phone: +41 44 634 46 79
- 24
- 25 Keywords: SARS-CoV-2, vaccination, adverse effects, hesitancy, real-world data

26

- 27 Running title: SARS-CoV-2 vaccination adverse effects
- 28
- 29 Main Points: Our representative population-based cohort study demonstrated the safety of
- 30 three SARS-CoV-2 vaccines and provides real-world estimates on adverse effect incidence.
- 31 Transparent communication of expected adverse effects to vaccine-seeking individuals is pivotal
- 32 to build trust in current or future vaccination campaigns.

It is made available under a CC-BY-NC-ND 4.0 International license .

## 34 Abstract

35	Importance: Long-term control of SARS-CoV-2 requires effective vaccination strategies. This has
36	been challenged by public mistrust and spread of misinformation regarding vaccine safety.
37	Hence, better understanding and communication on the longer-term and comparative
38	experiences of general population individuals following SARS-CoV-2 vaccination are required.
39	
40	Objective: To evaluate and compare self-reported adverse effects following SARS-CoV-2
41	vaccination, participants' perceptions regarding vaccinations and their compliance with
42	recommended public health measures.
43	
44	Design, Setting and Participants: Population-based longitudinal cohort of 575 adults, randomly
45	selected from all individuals presenting to the reference vaccination center of the Canton of
46	Zurich, Switzerland, for receipt of BNT162b2, mRNA1273, or JNJ-78436735.
47	
48	Exposures: BNT162b2, mRNA1273, or JNJ-78436735 vaccines.
49	
50	Main Outcomes and Measures: Primary outcomes included period prevalence, onset, duration,
51	and severity of self-reported adverse effects over 12 weeks following vaccination with a specific
52	focus on the proportion of participants reporting allergic reactions, menstrual irregularities, or
53	cardiac adverse effects, or requiring hospitalization. Secondary outcomes included risk factors
54	associated with reporting adverse effects, perception of vaccine importance, trust in public

It is made available under a CC-BY-NC-ND 4.0 International license .

health authorities and pharmaceutical companies, and compliance with recommended publichealth measures.

57

58 **Results**: 454 (79.0%) participants reported at least one adverse effect during 12 weeks after 59 vaccination. Prevalence was highest among mRNA-1273 recipients (88.7% vs. 77.3% after 60 BNT162b2, 69.1% after JNJ-78436735). Most adverse effects were systemic (72%), occurred 61 within 24 hours (67.9%), and resolved in less than three days (76.3%). 85.2% were reported as 62 mild or moderate. Allergic reactions were reported by 0.4% of participants, hospitalizations by 63 0.7%, cardiac adverse effects by 1.4%. Menstrual irregularities were reported by 9% of female 64 participants younger than 50 years. Female sex, younger age, higher education, and receipt of mRNA-1273 were associated with reporting adverse effects. Compared to JNJ-78436735 65 66 recipients, a higher proportion of mRNA vaccine recipients agreed that vaccination is important 67 (87.5% vs. 28.5%), and trusted public health authorities (80.2% vs. 30.3%) and pharmaceutical 68 companies (71.7% vs. 23.6%).

69

70 Conclusions and Relevance: Our population-based cohort provided real-world data on self-71 reported adverse effects following SARS-CoV-2 vaccination and highlights the importance of 72 transparent communication regarding adverse effects and building trust in public health 73 authorities to ensure successful future vaccination campaigns.

It is made available under a CC-BY-NC-ND 4.0 International license .

### 75 Introduction

76 Beginning with the first vaccinations against SARS-CoV-2 in December 2020, the largest global 77 vaccination campaign in recent history captured the public and professional attention for 78 months. Apart from the obvious focus on efficacy, concerns about vaccine-related adverse 79 effects dominated the professional and public discourse during the campaign. The fast-track 80 authorization of the technologically new mRNA vaccines BNT162b2 (Pfizer-BioNTech) and 81 mRNA1273 (Moderna) in some countries and misinformation contributed to vaccine skepticism 82 and hesitancy.[1-5] This highlights the importance of understanding and accurately 83 communicating information regarding adverse effects, including vaccine safety profiles, to 84 improve vaccine confidence and uptake.

85 The current body of evidence on adverse effects following SARS-CoV-2 vaccination consists 86 mostly of data reported in randomized clinical trials (RCTs) and reports to government-based 87 surveillance systems, such as the European EudraVigilance, US VAERS (Vaccine Adverse Event 88 Reporting System), or Swiss ElViS (Electronic Vigilance System). Adverse effects reported in RCTs 89 have been primarily mild and self-limited, [6, 7] with systemic reactions (e.g. fatigue, headache, 90 pain) and local injection site reactions (e.g. pain, erythema, swelling) being the most frequent.[8-91 10] In contrast, severe adverse effects accounted for a significantly higher proportion of reports 92 in governmental surveillance systems. [11-13] This was to be expected as reporting to surveillance 93 systems is subject to several biases including underreporting of mild and common adverse effects 94 and increased reporting of those which are severe or widely reported in the media. [14, 15] 95 Although RCTs provided important evidence on the safety of individual vaccines, they offered 96 little side-by-side comparisons. Furthermore, RCTs yield data collected on selected populations

It is made available under a CC-BY-NC-ND 4.0 International license .

97 raising the issue of how well this data correlates to "real-world" experiences. The few studies 98 eliciting patient-reported symptoms following different vaccines in real-world settings often had 99 cross-sectional designs and were conducted among very specific groups such as healthcare 100 workers or university students, which may not be representative of the general population.[6, 7] 101 In this population-based study, we aimed to deliver a comprehensive comparative analysis of 102 self-reported adverse effects up to 12 weeks after receipt of three SARS-CoV-2 vaccines approved 103 in Switzerland in 2021. Further objectives were to examine the general perception and attitudes 104 of individuals regarding SARS-CoV-2 vaccination and their compliance with recommended public 105 health measures. Thereby, we aim to improve our understanding of the adverse health effects 106 experienced following vaccination in the general population to provide an evidence base for 107 future vaccination campaigns in view of the likely implementation of additional booster 108 vaccinations and updated SARS-CoV-2 vaccines.

109

#### 110 Methods

### 111 Study design, participants, and recruitment


This study is based on the Zurich SARS-CoV-2 Vaccine Cohort, an ongoing prospective populationbased cohort study. We recruited participants between March 10, 2021, and January 27, 2022, at the University of Zurich's (UZH) vaccination center, the reference center for the Canton of Zurich, Switzerland. All individuals scheduled to receive one of the SARS-CoV-2 vaccines approved in Switzerland in 2021, BNT162b2 (Pfizer-BioNTech), mRNA1273 (Moderna), or JNJ-78436735 (Johnson & Johnson), were screened for eligibility. Eligibility criteria were being 18 years or older,

It is made available under a CC-BY-NC-ND 4.0 International license .

118 being able to follow study procedures, having sufficient knowledge of the German language and 119 residing in the Canton of Zurich. We excluded individuals who had already received a first dose 120 of a SARS-CoV-2 vaccine. A daily age-stratified (18-64 years, 65 years or older) random sample 121 was selected separately for each approved vaccine from all eligible individuals belonging to the 122 following vaccination groups as defined by the Canton of Zurich [16, 17]: "Over 75 years", "over 123 65 years", "between 50-64 years", and "between 18-49 years". We excluded individuals 124 belonging to groups specific for "healthcare workers", "caretakers of high-risk patients", 125 "individuals living in communal facilities", and "individuals with the highest risk diseases" to 126 ensure that that our sample was representative of the general population. [18, 19] Randomly 127 selected individuals were then invited to participate in our study. We obtained written informed 128 consent from all participants. We were unable to reach the desired sample size for JNJ-78436735 129 recipients 65 years or older, due to limited demand. 130 The study protocol was prospectively registered on the International Standard Randomized

131 Controlled Trial Number Registry (ISRCTN 15499304) and approved by the ethics committee of 132 the Canton of Zurich (BASEC 2021-00273).

#### It is made available under a CC-BY-NC-ND 4.0 International license .



133

134 **Figure 1.** Recruitment of study cohort

135

### 136 Data sources and measurements

Upon enrolment, all participants completed a baseline questionnaire including questions on their sociodemographics, medical and smoking history, SARS-CoV-2 related information such as prior infections, perceptions and attitudes regarding vaccination, trust in public health authorities and pharmaceutical companies, and compliance with recommended public health measures (including use of the SwissCovid digital proximity tracing app). Perception, attitude, and

It is made available under a CC-BY-NC-ND 4.0 International license .

142 compliance questions were collected using a numerical scale (0 "Very low opinion", to 100 "Very 143 high opinion" for perception), or a 5-item Likert (ranging from "Strongly disagree" to "Strongly 144 agree" for trust-related statements, and from "Never/Impossible" to "Always" for statements on 145 compliance with public health measures). We pooled BNT162b2 and mRNA-1273 recipients into 146 one "mRNA vaccine" group since they expressed similar perceptions towards vaccination and 147 compliance with recommended measures (Supplement 1).

148 We provided participants with a paper symptom diary and instructed them to record any adverse 149 effect they experienced during 12 weeks after vaccination, as free text, including start and end 150 dates, perceived severity (on a 5-item Likert scale, ranging from "Very mild" to "Very severe"), 151 and consequences of the adverse effects (i.e., self-medication, need for healthcare services, or 152 hospitalizations). Symptom diaries were collected at the 12-week follow-up visit. Participants 153 received additional electronic questionnaires at 4, 6, and 12 weeks, in which they were asked to 154 report any positive SARS-CoV-2 polymerase chain reaction (PCR) or rapid antigen tests. We 155 excluded all reported adverse effects starting within three days before and at any timepoint after 156 positive SARS-CoV-2 tests to ensure that reported symptoms were related to vaccination rather 157 than infection. To determine the proportion of participants with past SARS-CoV-2 infection, we 158 measured participants' anti-SARS-CoV-2 Spike (S)-IgA and IgG antibodies at baseline using a 159 highly sensitive and specific Luminex technology-based assay. [20] 160 We collected and managed all study data using the Research Electronic Data Capture (REDCap)

161 system.[21, 22]

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 163 Outcomes

Our primary outcomes included period prevalence, onset, duration, and severity of self-reported adverse effects over 12 weeks following vaccination, with a specific focus on the proportion of participants reporting allergic reactions, menstrual irregularities, or cardiac adverse effects, or requiring hospitalization. Secondary outcomes included risk factors associated with adverse effect reports, general perceptions and attitudes regarding vaccination, trust in public health authorities and pharmaceutical companies, and compliance with recommended public health measures.

171

### 172 Statistical Analysis

173 We descriptively analyzed the characteristics and outcomes of interest for the overall cohort and 174 for each of the three vaccine groups. Continuous variables are reported as median with 175 interguartile range (IQR); categorical or ordinal variables as frequencies (N) and percentages 176 (%).We coded adverse effect data reported by participants in the symptom diary according to 177 the Medical Dictionary for Regulatory Activities (MedDRA) hierarchical terminology (Supplement 2).[23] The self-reported adverse effects were translated from German to the closest matching 178 179 MedDRA "low level term". All corresponding higher-level terms were included in the database, a 180 highest level of coding was added, labelling each adverse effect either as "local" or "systemic". 181 We explored associations of several predictor variables on the outcome of reporting one or more 182 adverse effects using a multivariable logistic regression model. Age, sex, vaccine type and 183 education were included a priori variables in the model based on findings from other studies.[6]

It is made available under a CC-BY-NC-ND 4.0 International license .

- 184 Results are presented as odds ratios (OR) with their 95% confidence intervals (CI) and two-sided
- 185 p-value. All analyses were performed using R (version 4.1.2).
- 186

187 **Results** 

- 188 **Cohort characteristics**
- 189 Of our 575 participants, 323 participants (56.2%) were female, and the median age was 59 years
- 190 (IQR 41 to 70) (Table 1). 411 (71.5%) participants received a mRNA-based vaccine (2 doses 3 to 4
- 191 weeks apart, 36.2% BNT162b2 and 35.3% mRNA-1273) and 164 (28.5%) received a vector-based
- vaccine (1 dose, JNJ-78436735). The proportion of participants with a higher level of education
- 193 (39.8% vs 61.8%) was lower among JNJ-78436735 recipients compared to mRNA vaccine
- 194 recipients.
- 195 37 participants (6.4%) reported ever having a positive SARS-CoV-2 test prior to vaccination, with
- a higher proportion among JNJ-78436735 recipients (9.7% vs 6.4% of mRNA-1273 and 3.7% of
- 197 BNT162b2 recipients). 19 (9.2%) BNT162b2 recipients, 24 (11.8%) mRNA-1273 recipients and 29
- 198 (17.6%) JNJ-78436735 recipients tested seropositive for anti-SARS-CoV-2 S-IgA or -IgG before
- 199 receiving the first vaccination dose.
- 200

It is made available under a CC-BY-NC-ND 4.0 International license .

### 201 **Table 1.** Demographic and clinical characteristics of study population

	BNT162b2	mRNA-1273	JNJ-78436735 (Johnson & Johnson)	Overall
	(Pfizer/BioNTech)	(Moderna)		
	(N=207)	(N=203)	(N=165)	(N=575)
Age, median (IQR) -in years	59 (36 to 75)	65 (42.5 to 69)	58 (45 to 70)	59 (41 to 70)
Age distribution - no. of participants (%)				
<65 years	106 (51.2%)	99 (48.8%)	103 (62.4%)	308 (53.6%)
≥65 years	101 (48.8%)	104 (51.2%)	62 (37.6%)	267 (46.4%)
Female sex - no. of participants (%)	115 (55.6%)	120 (59.1%)	88 (53.3%)	323 (56.2%)
Presence of at least one preexisting	80 (40.8%)	78 (42.2%)	64 (43.2%)	222 (42.0%)
medical condition (%)				
Highest educational level - no. of				
participants (%)				
None or mandatory school	9 (4.4%)	4 (2.0%)	7 (4.3%)	20 (3.5%)
Vocational training or specialized	71 (34.5%)	72 (35.6%)	91 (55.8%)	234 (41.0%)
baccalaureate				
Higher technical school or college	46 (22.3%)	44 (21.8%)	40 (24.5%)	130 (22.8%)
University	80 (38.8%)	82 (40.6%)	25 (15.3%)	187 (32.7%)
Missing	1 (0.5%)	1 (0.5%)	2 (1.2%)	4 (0.7%)
Reported adverse effects - no. of	160 (77.3%)	180 (88.7%)	114 (69.1%)	456 (79.3%)
participants (%)				
Tested seropositive for anti-SARS-CoV-2	12 (5.8%)	14 (6.9%)	20 (12.1%)	46 (8.0%)
S-IgA at baseline - no. of participants (%)				
Tested seropositive for anti-SARS-CoV-2	15 (7.2%)	19 (9.4%)	24 (14.5%)	58 (10.1%)
S-IgG at baseline - no. of participants (%)				

It is made available under a CC-BY-NC-ND 4.0 International license .

Reported positive SARS-CoV-2 test prior	8 (3.9%)	13 (6.4%)	16 (9.7%)	37 (6.4%)
to baseline - no. of participants (%)				
SARS-CoV-2 Infection prior to baseline	21 (10.1%)	28 (13.8%)	31 (18.8%)	80 (13.9%)
(self-reported infection or tested				
seropositive)- no. of participants (%)				
Tested positive for anti-SARS-CoV-2 S-	13 (6.3%)	15 (7.4%)	15 (9.1%)	43 (7.5%)
IgA or IgG at baseline with no report of				
prior SARS-CoV-2 Infection- no. of				
participants (%)				

202

#### 203 Frequency and characteristics of adverse effects

204 Overall, 79.0% (N= 454) of all participants reported at least one adverse effect up to three months 205 following vaccination, with a total of 2397 reported adverse effects. The highest proportion of 206 participants with adverse effects after vaccination was among mRNA-1273 recipients (88.7%, 207 N=180) compared to BNT162b2 (77.3%, N=160) and JNJ-78436735 (69.1%, N=114) recipients. 208 Based on a multivariable logistic regression model, we found strong to very strong evidence that 209 female sex (OR=4.05 (95% CI: 2.33 to 7.3), p<0.001), higher education levels (vs. none or 210 mandatory school, OR=6.26 (1.86 to 21.2), p=0.003) and receiving mRNA-1273 (vs. BNT162b2, 211 OR=2.38 (1.22 to 4.8), p=0.013) were associated with adverse effect reports. There was weak 212 evidence that younger age (<65 vs.  $\geq$ 65 years, OR=1.65 (0.96 to 2.9), p=0.072) was associated 213 with adverse effects. We found no evidence that JNJ-78436735 (vs. BNT162b2), preexisting 214 conditions, low opinion (opinion value <50) about vaccination and SARS-CoV-2 infections prior to 215 vaccination were associated with adverse effects (Supplement 3).

It is made available under a CC-BY-NC-ND 4.0 International license .

216 More participants reported systemic (71.7%, N=412) than local adverse effects (54.8%, N=315). 217 Among mRNA vaccine recipients, the proportion of systemic among all adverse effects increased 218 after the 2<sup>nd</sup> dose (63.9% to 77.2% in BNT162b2 and 59.1% to 78.0% in mRNA-1273 recipients, 219 Supplement 4). The most common adverse effect mentioned by mRNA vaccine recipients was 220 local pain (54.1% of BNT162b2 and 69.5% of mRNA-1273 recipients), followed by asthenia 221 (fatigue; 38.7% of BNT162b2 and 44.8% of mRNA-1273 recipients). JNJ-78436735 recipients most 222 frequently reported headache (36.4%), followed by local pain (30.9%) and asthenia (30.9%). 223 Other commonly reported adverse effects included nausea, vertigo, and sore throat (all >5%). Of 224 our participants, 0.4% (n=2) (one BNT162b2 and one mRNA-1273 recipient) reported allergic 225 reactions. Adverse effects affecting menstruation were reported by 5 out of 47 (10.6%) female 226 participants younger than 50 among BNT162b2 recipients, 4 out of 42 (9.5%) among mRNA-1273 227 recipients and 2 out of 31 (6.5%) among JNJ-78436735 recipients (six participants reported cycle 228 irregularities, three heavy menstrual bleeding, three intermenstrual bleeding). Tachycardia or 229 palpitations were reported by seven (1.2%) participants, four mRNA-1273, two JNJ-78436735 and 230 one BNT162b2 recipient. One BNT162b2 recipient reported pericardial effusion and atrial 231 fibrillation after the second dose. 232 Most adverse effects (83.9%) occurred in the first week following vaccination, 67.9% within 24

hours. Participants reported that adverse effects lasted for 3.9 days on average, and most resolved within 3 (76.3%) days. Asthenia, extremity pain, and cough were most frequently reported to last longer than a week. Adverse effect onset and duration were similar across the three vaccines (Figure 2A, Supplement 5).

It is made available under a CC-BY-NC-ND 4.0 International license .

237 The perceived severity of most adverse effects was mild (49.0%) or moderate (36.2%). 238 Meanwhile, 14.7% were described as severe (13.4%) or very severe (1.3%), with the highest 239 proportion of severe to very severe adverse effects reported after JNJ-78436735 (18.3% vs 16.1% 240 after mRNA-1273, 9.4% after BNT162b2). Asthenia (13.1%), headache (12.8%) and pain (9.4%) 241 were mostly reported as severe or very severe adverse effects. Hospitalization due to reported 242 adverse effects was reported by 0.7% (n=4) of participants (two BNT162b2 recipients with loss of 243 consciousness and bullous pemphigoid, one mRNA-1273 recipient with retinal detachment and 244 one JNJ-78436735 recipient with meningitis). 245 Most reported adverse effects resolved spontaneously (Figure 2C). However, participants 246 reported using self-prescribed medications (e.g., Paracetamol or Ibuprofen) or seeking 247 consultation with a healthcare provider for 448 (18.7%) and 84 (3.5%) of the adverse effects,

248 respectively.

It is made available under a CC-BY-NC-ND 4.0 International license .





Figure 2. Frequency of any, local and systemic adverse effects. Panel A shows five most common systemic and local
 adverse effects in overall sample (N=575). Panel B shows adverse effects by vaccine type (BNT162b2 N=208, mRNA-

252 1273 N=203, JNJ-78436735 N=164).

It is made available under a CC-BY-NC-ND 4.0 International license .



253

Figure 3. Characteristics of self-reported adverse effects. Panel A shows the time of adverse effect onset by vaccine,
 panel B perceived adverse effect severity by vaccine and panel C the consequences of adverse effects by vaccine.
 (ER: Emergency Room)

257

#### 258 Perceptions of vaccination and compliance with recommended public health measures


259 More mRNA vaccine recipients (87.5%) agreed completely or in part with the statement that it

was important to be vaccinated compared to 28.5% of JNJ-78436735 recipients. Similarly, more

- 261 mRNA vaccine recipients felt that vaccines were a part of a healthy lifestyle (63.6% vs. 28.9% of
- 262 JNJ-78436735 recipients). Trust in public health authorities (80.2% vs. 30.3%) and pharmaceutical
- 263 companies (71.7% vs. 23.6%) was higher among mRNA vaccine recipients compared to JNJ-

It is made available under a CC-BY-NC-ND 4.0 International license .

264 78436735 recipients. Both groups felt they had sufficient understanding of how the vaccine 265 helped the body fend off infectious diseases (89.3% mRNA vaccine recipients vs. 62.4% JNJ-266 78436735 recipients) and reported similar compliance with recommended public health 267 measures (Figure 3B). Use of the SwissCovid digital proximity tracing app was higher among 268 mRNA vaccine recipients compared to JNJ-78436735 recipients (53.2% vs 27.4%).





It is made available under a CC-BY-NC-ND 4.0 International license .

### 272 **Discussion**

273 In this population-based cohort of 575 individuals who received a SARS-CoV-2 vaccine and were 274 followed-up over 12 weeks, participants commonly reported adverse effects, namely local pain, 275 fatigue, headache, and fever. Most adverse effects were mild to moderate and resolved within 276 three days. Allergic reactions (0.4%) and adverse effects requiring hospitalization (0.7%) were 277 rare. Around 9% of female participants younger than 50 reported menstrual cycle changes, more 278 frequently among mRNA vaccine recipients. Female sex, receiving mRNA-1273, higher education 279 and younger age were associated with experiencing adverse effects. JNJ-78436735 recipients less 280 frequently perceived vaccination to be important and had lower trust in public health authorities 281 and pharmaceutical companies compared to mRNA vaccine recipients. There were no differences 282 between vaccine groups in compliance with preventive public health measures. 283 Our results on the prevalence and severity of adverse effects are in line with previously 284 reported data from RCTs and other observational studies. [6, 9, 10, 24-26] In an online survey 285 among individuals vaccinated with either BNT162b2, mRNA-1273, or JNJ-78436735, Beatty et 286 al. reported that 80.3% of participants experienced adverse effects, with comparable estimates 287 for each vaccine type.[6] Our data also matches the prevalence published in the RCTs for each 288 vaccine individually.[8-10]. The proportion of adverse effects that were self-assessed to be 289 severe or required hospitalization in our study (14.8%) was well below that of Swiss and 290 European governmental surveillance systems (37.9% in Swiss ElViS).[11, 12] US surveillance 291 reports also stated higher estimates of serious adverse events based on hospitalization rates, 292 serious illness and deaths (9.2% vs. our 0.7%).[13] These higher estimates from governmental 293 reporting systems are likely related to the underreporting of mild symptoms and underscore

It is made available under a CC-BY-NC-ND 4.0 International license .

294	the importance of "real-world" data.[14, 15] There is wide variation in reports on prevalence of
295	anaphylaxis and severe allergic reactions ranging from 0.03% to 3%, due to differing
296	definitions.[6, 27, 28] In our study, two (0.4%) participants reported allergic reactions, without
297	requiring medical attention.
298	Our follow-up over 12 weeks allowed us to assess adverse effects that occur with some delay,
299	such as menstrual changes reported in 9% of female participants younger than 50 years. Few
300	studies have described menstrual irregularities following SARS-CoV-2 vaccination with
301	prevalence ranging between 0.3% and 46%.[29, 30] This large variability and the high prevalence
302	(37.8%) of menstrual irregularities in the general population regardless of vaccination underscore
303	the challenge of attributing changes in the menstrual cycle to vaccination.[31] Further research
304	is needed on the influence of SARS-CoV-2 vaccination on menstruation and the general impact
305	of vaccination on female recipients, as we and others observed that female recipients were
306	generally more likely to experience adverse effects.[32-35]
307	We also found that participants who were younger than 65 years and received mRNA-1273 were
308	more likely to report adverse effects possibly due to stronger immune responses among these
309	groups.[6, 13, 26] Similarly, other studies have found evidence that SARS-CoV-2 infections prior
310	to vaccination may be associated with adverse effects reports due to increased
311	immunogenicity.[6, 7] While we found that individuals with prior SARS-CoV-2 infections were 1.8
312	times more likely to report adverse effects compared to those without, the findings were not
313	statistically significant, potentially due to insufficient power in our study.
314	mRNA vaccine recipients trusted vaccines in general and thus were mostly motivated to be
015	

vaccinated as soon as SARS-CoV-2 vaccines became available. JNJ-78436735 recipients were

315

It is made available under a CC-BY-NC-ND 4.0 International license .

316 more hesitant and waited for JNJ-78436735's introduction to Switzerland, resulting in a higher 317 proportion of individuals with infections prior to vaccination compared to mRNA vaccine 318 recipients. Other studies describe these concerns about the rapid development and fears of 319 adverse effects to be among the main reasons to wait for non-mRNA-based vaccines or other 320 alternatives. [36-38] General skepticism and the presence of nocebo effects, as demonstrated by 321 a Amanzio et al, may have translated into a higher proportion of JNJ-78436735 recipients 322 perceiving adverse effects as severe. [38-40] Increasing awareness of these nocebo responses 323 and using positive framing around the low risk of severe adverse effects may contribute to 324 improving vaccine acceptance.

This study provided evidence from a representative cohort recruited from the general population and followed-up over a 12-week period. Data collected through symptom diaries and adverse effect coding according to MedDRA terms generated a comprehensive dataset allowing a comparative analysis of three common SARS-CoV-2 vaccines.

329 However, there are several limitations to our study. First, self-selection bias may have occurred 330 if individuals who are more health literate or less hesitant participated in our study, leading to 331 overestimations of trust in public health authorities and more positive perceptions of vaccines. 332 However, we consider the data on the prevalence of adverse effects as broadly representative. 333 Second, our data is self-reported. While this allows for an accurate description of vaccine 334 recipients' experiences, it is subjective and no verification of the relation of adverse effects and 335 vaccination by a healthcare provider was possible. Third, the absolute numbers of reports for 336 some adverse effects when analyzed individually are relatively small (e.g., menstrual changes). 337 Finally, our analysis was restricted to basic immunization of the three SARS-CoV-2 vaccines

It is made available under a CC-BY-NC-ND 4.0 International license .

approved in Switzerland at the time of study conduct. Further research on adverse effects
 occurring after booster vaccinations, other types of vaccines and combinations of different
 vaccines is needed.

341

## 342 **Conclusion**

- 343 This study demonstrates the safety of three SARS-CoV-2 vaccines in a representative population-
- 344 based cohort and provides real-world estimates on adverse effect prevalence after vaccination.
- 345 Thereby, we importantly extend the evidence base for health-care providers to answer many of
- 346 the questions of individuals seeking vaccination. While further evidence on adverse effects after

booster vaccination and other vaccine types is required, our study suggests that transparent

- 348 communication regarding adverse effects and building trust in public health authorities are
- 349 pivotal future vaccination campaigns' success.

350

It is made available under a CC-BY-NC-ND 4.0 International license .

## 351 Funding

352	This work was supported by funds received within the Corona Immunitas research network, of
353	which this study is part of. The Corona Immunitas research network is coordinated by the Swiss
354	School of Public Health (SSPH+) and funded by fundraising of SSPH+ including funds of the Swiss
355	Federal Office of Public Health and private funders (ethical guidelines for funding stated by
356	SSPH+ were respected), by funds of the cantons of Switzerland (Vaud, Zurich, and Basel), and by
357	institutional funds of the Universities. Additional funding specific for this cohort was received
358	from the Uniscientia Foundation (Switzerland). TB received funding from the European Union's
359	Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant
360	agreement No 801076, through the SSPH+ Global PhD Fellowship Programme in Public Health
361	Sciences (GlobalP3HS) of the SSPH+. DM received funding by the UZH Postdoc Grant, grant no.
362	FK-22-053.

363

## 364 Acknowledgements

The authors thank the study administration team and the team from the University of Zurich's (UZH) vaccination center, the reference center for the Canton of Zurich, Switzerland, for their dedicated support of the study. They also thank the study participants for their valuable contribution to this project.

369

## 370 Conflict of Interest

371 The authors of this manuscript state no conflict of interest.

It is made available under a CC-BY-NC-ND 4.0 International license .

## 372 **References:**

- O'Callaghan KP, Blatz AM, Offit PA. Developing a SARS-CoV-2 Vaccine at Warp Speed.
   JAMA **2020**; 324(5): 437-8.
- US Food and Drug Administration. Pfizer-BioNTechCOVID-19 vaccine emergency use
   authorization. Available at: <u>https://www.fda.gov/media/144412/download</u>. Accessed
   June 22.
- US Food and Drug Administration. Moderna COVID-19 vaccine emergency use
   authorization. Available at: <u>https://www.fda.gov/media/144636/download</u>. Accessed
   June 22.
- Khubchandani J, Sharma S, Price JH, Wiblishauser MJ, Sharma M, Webb FJ. COVID-19
   Vaccination Hesitancy in the United States: A Rapid National Assessment. J Community
   Health 2021; 46(2): 270-7.
- 3845.Cascini F, Pantovic A, Al-Ajlouni Y, Failla G, Ricciardi W. Attitudes, acceptance and385hesitancy among the general population worldwide to receive the COVID-19 vaccines and
- 386 their contributing factors: A systematic review. EClinicalMedicine **2021**; 40: 101113.
- Beatty AL, Peyser ND, Butcher XE, et al. Analysis of COVID-19 Vaccine Type and Adverse
   Effects Following Vaccination. JAMA Netw Open **2021**; 4(12): e2140364.
- 3897.Mathioudakis AG, Ghrew M, Ustianowski A, et al. Self-Reported Real-World Safety and
- 390 Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey. Life (Basel) **2021**; 11(3).
- 391 8. Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S
- 392 Vaccine against Covid-19. N Engl J Med **2021**; 384(23): 2187-201.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 393 9. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-
- 394 19 Vaccine. N Engl J Med **2020**; 383(27): 2603-15.
- 395 10. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2
- 396 Vaccine. N Engl J Med **2021**; 384(5): 403-16.
- 397 11. Swissmedic. Reports of suspected adverse reactions to COVID-19 vaccines in Switzerland
- 398 update 26. Available at:
- 399 https://www.swissmedic.ch/swissmedic/en/home/news/coronavirus-covid-19/covid-
- 400 <u>19-vaccines-safety-update-16.html</u>. Accessed 19 August.
- 401 12. European Medicines Agency. Safety of COVID-19 Vaccines. Available at: 402 https://www.ema.europa.eu/en/human-regulatory/overview/public-health-
- 403 <u>threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/safety-</u>
- 404 <u>covid-19-vaccines</u>. Accessed August 24.
- 405 13. Gee J, Marquez P, Su J, et al. First Month of COVID-19 Vaccine Safety Monitoring United
- 406 States, December 14, 2020-January 13, 2021. MMWR Morb Mortal Wkly Rep **2021**; 70(8):
- 407 283-8.
- 408 14. Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the Vaccine
  409 Adverse Event Reporting System (VAERS). Vaccine **2015**; 33(36): 4398-405.
- 410 15. Rosenthal S, Chen R. The reporting sensitivities of two passive surveillance systems for
  411 vaccine adverse events. Am J Public Health **1995**; 85(12): 1706-9.
- 41216.CantonZurich.Coronavirusvaccination.Availableat:413<a href="https://www.zh.ch/en/gesundheit/coronavirus/coronavirus-impfung.html">https://www.zh.ch/en/gesundheit/coronavirus/coronavirus-impfung.html</a>.Accessed
- 414 **13th July**.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 415 17. TravelClinic.ch. Impfgruppen. Available at: travelclinic.ch/wp416 content/uploads/Impfgruppen.pdf. Accessed 13th July.
- 417 18. Federal Office of Public Health. Kategorien besonders gefährdeter Personen.
  418 bag.admin.ch: Federal Office of Public Health,, **2022** 10.08.2022.
- 419 19. Federal Office of Public Health. Covid-19-Impfstrategie (Stand 05.07.2022). bag.admin.ch:
- 420 Federal Office of Public Health,, **2022** 05.07.2022.
- 421 20. Fenwick C, Croxatto A, Coste AT, et al. Changes in SARS-CoV-2 Spike versus Nucleoprotein
- 422 Antibody Responses Impact the Estimates of Infections in Population-Based 423 Seroprevalence Studies. J Virol **2021**; 95(3).
- 424 21. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international 425 community of software platform partners. J Biomed Inform **2019**; 95: 103208.
- 426 22. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data
- 427 capture (REDCap)--a metadata-driven methodology and workflow process for providing
- 428 translational research informatics support. J Biomed Inform **2009**; 42(2): 377-81.
- 429 23. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA).
  430 Drug Saf **1999**; 20(2): 109-17.
- 431 24. Thomas SJ, Moreira ED, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-
- 432 19 Vaccine through 6 Months. N Engl J Med **2021**; 385(19): 1761-73.
- 433 25. Jęśkowiak I, Wiatrak B, Grosman-Dziewiszek P, Szeląg A. The Incidence and Severity of
- 434 Post-Vaccination Reactions after Vaccination against COVID-19. Vaccines (Basel) **2021**;
- 435 9(5).

It is made available under a CC-BY-NC-ND 4.0 International license .

- 436 26. Vigezzi GP, Lume A, Minerva M, et al. Safety surveillance after BNT162b2 mRNA COVID-
- 437 19 vaccination: results from a cross-sectional survey among staff of a large Italian teaching
- 438 hospital. Acta Biomed **2021**; 92(S6): e2021450.
- 439 27. Shimabukuro T. Allergic reactions including anaphylaxis after receipt of the first dose of
- 440 Pfizer-BioNTech COVID-19 vaccine United States, December 14-23, 2020. Am J
- 441 Transplant **2021**; 21(3): 1332-7.
- 442 28. Blumenthal KG, Robinson LB, Camargo CA, et al. Acute Allergic Reactions to mRNA COVID-
- 443 19 Vaccines. JAMA **2021**; 325(15): 1562-5.
- 444 29. Rogers A, Rooke E, Morant S, et al. Adverse events and overall health and well-being after
- 445 COVID-19 vaccination: interim results from the VAC4COVID cohort safety study. BMJ 446 Open **2022**; 12(6): e060583.
- 447 30. Lee KM, Junkins EJ, Fatima UA, Cox ML, Clancy KB. Characterizing menstrual bleeding
- 448 changes occurring after SARS-CoV-2 vaccination. medRxiv **2021**: 2021.10.11.21264863.
- 44931.Trogstad L. Increased occurrence of menstrual disturbances in 18-to 30-year-old women
- 450 after COVID-19 vaccination. Available at SSRN 3998180 **2022**.
- 451 32. Ruggieri A, Anticoli S, D'Ambrosio A, Giordani L, Viora M. The influence of sex and gender
- 452 on immunity, infection and vaccination. Ann Ist Super Sanita **2016**; 52(2): 198-204.
- 453 33. Klein SL, Marriott I, Fish EN. Sex-based differences in immune function and responses to 454 vaccination. Trans R Soc Trop Med Hyg **2015**; 109(1): 9-15.
- 455 34. Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and Gender Differences in the Outcomes
- 456 of Vaccination over the Life Course. Annu Rev Cell Dev Biol **2017**; 33: 577-99.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 457 35. Fischinger S, Boudreau CM, Butler AL, Streeck H, Alter G. Sex differences in vaccine-
- 458 induced humoral immunity. Semin Immunopathol **2019**; 41(2): 239-49.
- 459 36. Wadman M. Novavax's long-awaited COVID-19 vaccine authorizations offer an alternative
- 460 to mRNA. Available at: <u>https://www.science.org/content/article/novavax-s-long-</u>
- 461 <u>awaited-covid-19-vaccine-authorizations-offer-alternative-mrna</u>. Accessed July 7th.
- 462 37. Wong MCS, Wong ELY, Cheung AWL, et al. COVID-19 Vaccine Hesitancy in a City with Free
- 463 Choice and Sufficient Doses. Vaccines (Basel) **2021**; 9(11).
- 464 38. Latkin C, Dayton L, Yi G, Jaleel A, Nwosu C, Limaye R. COVID-19 vaccine delay: An
- 465 examination of United States residents' intention to delay vaccine uptake. Hum Vaccin
  466 Immunother **2021**; 17(9): 2903-13.
- 467 39. Planès S, Villier C, Mallaret M. The nocebo effect of drugs. Pharmacol Res Perspect **2016**;
- 468 4(2): e00208.
- 469 40. Amanzio M, Mitsikostas DD, Giovannelli F, Bartoli M, Cipriani GE, Brown WA. Adverse
- 470 events of active and placebo groups in SARS-CoV-2 vaccine randomized trials: A
- 471 systematic review. Lancet Reg Health Eur **2022**; 12: 100253.

472